

CLAIMS

1. An aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is bactericidal against serogroups B, C, W135 and Y of *N.meningitidis*, wherein the composition comprises: (i) a conjugated serogroup C capsular saccharide antigen;
5 (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; and (iv) one or more polypeptide antigens from serogroup B.
2. The composition of claim 1, further comprising: (v) a conjugated serogroup A capsular saccharide antigen.
3. The composition of claim 2, wherein the serogroup A capsular saccharide is modified such that at
10 least 20% of its monosaccharide units do not have -OH at either of the 3 and 4 positions.
4. The composition of claim 2 or claim 3, wherein the composition can be stored for 28 days at 37°C and, after that period, less than 20% of the initial total amount of conjugated MenA saccharide will be unconjugated.
5. The composition of any preceding claim, wherein the conjugated saccharides are
15 oligosaccharides.
6. The composition of any preceding claim, wherein the saccharides are conjugated to a carrier protein selected from: diphtheria toxoid, tetanus toxoid, *H.influenzae* protein D, and CRM₁₉₇.
7. The composition of any preceding claim, wherein the composition further comprises from 1 to 10 defined serogroup B polypeptide antigens, and wherein the composition can induce an immune
20 response that is bactericidal against two three of hypervirulent lineages A4, ET 5 and lineage 3 of *N.meningitidis* serogroup B.
8. The composition of claim 7, comprising one or more of the following five antigens: (i) a 'NadA' protein in oligomeric form; (ii) a '741' protein; (iii) a '936' protein; (iv) a '953' protein; and (v) a '287' protein.
9. The composition of claim 8, comprising: a first polypeptide comprising amino acid sequence
25 SEQ ID NO:2; a second polypeptide comprising amino acid sequence SEQ ID NO:7; and a third polypeptide comprising amino acid sequence SEQ ID NO:8;
10. The composition of any preceding claim, further comprising a saccharide antigen that protects against *H.influenzae* type B (Hib).
11. The composition of any preceding claim, further comprising an antigen that protects against
30 *Streptococcus pneumoniae*.
12. The composition of any preceding claim, comprising an aluminium phosphate adjuvant.
13. The composition of any preceding claim, packaged in a hermetically-sealed container.

14. The composition of claim 13, wherein the container is a vial or a syringe.
15. The composition of any preceding claim, for use as a medicament.
- 5 16. The use of a (i) a conjugated serogroup C capsular saccharide antigen; (ii) a conjugated serogroup W135 capsular saccharide antigen; (iii) a conjugated serogroup Y capsular saccharide antigen; (iv) one or more polypeptide antigens from serogroup B; and, optionally, (v) a conjugated serogroup A capsular saccharide antigen, in the manufacture of a medicament for raising an immune response in a mammal.
17. A method for raising an antibody response in a mammal, comprising administering a composition of any one of claims 1 to 15 to the mammal.
- 10 18. An aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is (a) bactericidal against at least serogroup W135 of *N.meningitidis* and (b) protective against *H.influenzae* type b disease, wherein the composition comprises: (i) a conjugated serogroup W135 capsular saccharide antigen; (ii) a conjugated *H.influenzae* type b capsular saccharide antigen.
- 15 19. The composition of claim 18, further comprising conjugated capsular saccharide antigens from serogroups C and Y and, optionally, A.
20. The composition of claim 18 or claim 19, further comprising one or more polypeptide antigens from serogroup B of *N.meningitidis*.